Skip to main content

Table 3 Responses at EOT and secondary timepoints in the MITT population and early switch subpopulation

From: Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial

 

MITT population

Early switch subpopulation

(n = 250)

(n = 102)

Response

n/N (%) [95% CI]a

n/N (%) [95% CI]a

Global response at EOT

  

 Success

170/203 (83.7) [78.7–88.8]

81/ 90 (90.0) [83.8–96.2]

 Sensitivity analysis*

170/250 (68.0) [62.2–73.8]

81/102 (79.4) [71.6–87.3]

 Failure

33

9

 Missing/unknown

47

12

Clinical response at EOT

  

 Success

174/187 (93.0) [89.4–96.7]

83/ 89 (93.3) [88.0–98.5]

 Sensitivity analysis*

174/250 (69.6) [63.9–75.3]

83/102 (81.4) [73.8–88.9]

 Failure

13

6

 Missing/unknown

63

13

Microbiological response at EOT

  

 Success

183/192 (95.3) [92.3–98.3]

87/ 90 (96.7) [93.0–100.0]

 Sensitivity analysis*

183/250 (73.2) [67.7–78.7]

87/102 (85.3) [78.4–92.2]

 Failure

9

3

 Missing/unknown

58

12

Global response at secondary time points

n/N (%) [95% CI]

n/N (%) [95% CI]

 EOIV

208/235 (88.5) [84.4–92.6]

97/101 (96.0) [92.2–99.8]

  Sensitivity analysis*

208/250 (83.2) [78.6–87.8]

97/102 (95.1) [90.9–99.3]

 Week 2 follow-up

148/194 (76.3) [70.3–82.3]

72/ 86 (83.7) [75.9–91.5]

  Sensitivity analysis*

148/250 (59.2) [53.1–65.3]

72/102 (70.6) [61.7–79.4]

 EOS

131/187 (70.1) [63.5–76.6]

68/ 86 (79.1) [70.5–87.7]

  Sensitivity analysis*

131/250 (52.4) [46.2–58.6]

68/102 (66.7) [57.5–75.8]

  1. *Missing/unknown values set as failures; a95% CI based on normal approximation to the binomial.
  2. Abbreviations used: CI, confidence interval; EOIV, end of intravenous treatment; EOS, end of study; EOT, end of treatment; MITT, modified intent-to-treat.